Share Prices & Company Research

Market News

02 Apr 2019 | 10:05

Clinigen Group completes acquisition of the US rights to Proleukin

Clinigen Group completed the acquisition of the US rights to Proleukin following US anti-trust clearance. 'Proleukin is indicated for metastatic melanoma and metastatic renal cell carcinoma in the US and it is currently being used in around 80 active clinical studies within the US across multiple disease areas,' the company said. The Group now owned the global rights to Proleukin, having acquired the rest of world rights in July 2018. The acquisition would be modestly earnings per share accretive in the current financial year as the product transitions to Clinigen, and at least 25% accretive in the first full financial year, Clinigen added. Proleukin would become Clinigen's largest product in its Commercial Medicines division and it further diversified the Commercial Medicines owned portfolio of niche hospital and critical care products. 'Proleukin also presents opportunities to the wider Group as a whole, as it provides a platform to expand our existing footprint in the US, the biggest global pharmaceutical market, and will enable us to exploit other opportunities across the business,' said Shaun Chilton, Group Chief Executive Officer, Clinigen.

At 10:05am: (LON:CLIN) Clinigen Group share price was +5p at 918.5p

Story provided by
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.